Merck (NYSE: MRK) reported Q1 EPS of $0.88, $0.05 better than the analyst estimate of $0.83. Revenue for the quarter came in at $9.4 billion versus the consensus estimate of $9.25 billion.

• First-Quarter 2017 Worldwide Sales Were $9.4 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange
• First-Quarter 2017 GAAP EPS Was $0.56; First-Quarter Non-GAAP EPS Was $0.88
• Company Narrows and Raises 2017 Full-Year Revenue Range to be Between $39.1 Billion and $40.3 Billion, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange
• Company Narrows and Raises 2017 Full-Year GAAP EPS Range to be Between $2.51 and $2.63; Narrows and Raises 2017 Full-Year Non-GAAP EPS Range to be Between $3.76 and $3.88, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange
• KEYTRUDA Development Program Advances with Two Additional Regulatory Approvals and CHMP Positive Opinion; Four sBLAs Currently Under Priority Review with PDUFA Action Dates in Second Quarter

GUIDANCE:

Merck sees FY2017 EPS of $3.76-$3.88, versus the consensus of $3.81. Merck sees FY2017 revenue of $39.1-40.3 billion, versus the consensus of $39.72 billion.

For earnings history and earnings-related data on Merck (MRK) click here.